vs
Side-by-side financial comparison of GoPro, Inc. (GPRO) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
GoPro, Inc. is the larger business by last-quarter revenue ($201.7M vs $196.9M, roughly 1.0× Pacira BioSciences, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs 0.4%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $15.0M). Over the past eight quarters, GoPro, Inc.'s revenue compounded faster (13.9% CAGR vs 8.5%).
GoPro, Inc. is an American technology company founded in 2002 by Nick Woodman. It manufactures action cameras and develops its own mobile apps and video-editing software. Founded as Woodman Labs, Inc, the company is based in San Mateo, California.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
GPRO vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $201.7M | $196.9M |
| Net Profit | — | — |
| Gross Margin | 31.8% | 79.5% |
| Operating Margin | -4.1% | 1.2% |
| Net Margin | — | — |
| Revenue YoY | 0.4% | 5.1% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.06 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $201.7M | $196.9M | ||
| Q3 25 | $162.9M | $179.5M | ||
| Q2 25 | $152.6M | $181.1M | ||
| Q1 25 | $134.3M | $168.9M | ||
| Q4 24 | $200.9M | $187.3M | ||
| Q3 24 | $258.9M | $168.6M | ||
| Q2 24 | $186.2M | $178.0M | ||
| Q1 24 | $155.5M | $167.1M |
| Q4 25 | — | — | ||
| Q3 25 | $-21.3M | $5.4M | ||
| Q2 25 | $-16.4M | $-4.8M | ||
| Q1 25 | $-46.7M | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-8.2M | $-143.5M | ||
| Q2 24 | $-47.8M | $18.9M | ||
| Q1 24 | $-339.1M | $9.0M |
| Q4 25 | 31.8% | 79.5% | ||
| Q3 25 | 35.1% | 80.9% | ||
| Q2 25 | 35.8% | 77.4% | ||
| Q1 25 | 32.1% | 79.7% | ||
| Q4 24 | 34.7% | 78.7% | ||
| Q3 24 | 35.5% | 76.9% | ||
| Q2 24 | 30.5% | 75.1% | ||
| Q1 24 | 34.1% | 71.6% |
| Q4 25 | -4.1% | 1.2% | ||
| Q3 25 | -9.8% | 3.5% | ||
| Q2 25 | -9.2% | 4.7% | ||
| Q1 25 | -33.7% | 1.2% | ||
| Q4 24 | -19.5% | 13.2% | ||
| Q3 24 | -3.1% | -82.8% | ||
| Q2 24 | -25.0% | 15.9% | ||
| Q1 24 | -26.6% | 7.9% |
| Q4 25 | — | — | ||
| Q3 25 | -13.0% | 3.0% | ||
| Q2 25 | -10.8% | -2.7% | ||
| Q1 25 | -34.8% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -3.2% | -85.1% | ||
| Q2 24 | -25.7% | 10.6% | ||
| Q1 24 | -218.1% | 5.4% |
| Q4 25 | $-0.06 | $0.05 | ||
| Q3 25 | $-0.13 | $0.12 | ||
| Q2 25 | $-0.10 | $-0.11 | ||
| Q1 25 | $-0.30 | $0.10 | ||
| Q4 24 | $-0.22 | $0.38 | ||
| Q3 24 | $-0.05 | $-3.11 | ||
| Q2 24 | $-0.31 | $0.39 | ||
| Q1 24 | $-2.24 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.7M | $238.4M |
| Total DebtLower is stronger | $44.3M | $372.2M |
| Stockholders' EquityBook value | $76.5M | $693.1M |
| Total Assets | $428.0M | $1.3B |
| Debt / EquityLower = less leverage | 0.58× | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $49.7M | $238.4M | ||
| Q3 25 | $152.8M | $246.3M | ||
| Q2 25 | $58.6M | $445.9M | ||
| Q1 25 | $69.6M | $493.6M | ||
| Q4 24 | $102.8M | $484.6M | ||
| Q3 24 | $130.2M | $453.8M | ||
| Q2 24 | $133.0M | $404.2M | ||
| Q1 24 | $133.7M | $325.9M |
| Q4 25 | $44.3M | $372.2M | ||
| Q3 25 | $43.9M | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $0 | $585.3M | ||
| Q3 24 | $93.1M | — | ||
| Q2 24 | $92.9M | — | ||
| Q1 24 | $92.7M | — |
| Q4 25 | $76.5M | $693.1M | ||
| Q3 25 | $80.5M | $727.2M | ||
| Q2 25 | $97.9M | $757.8M | ||
| Q1 25 | $110.0M | $798.5M | ||
| Q4 24 | $151.7M | $778.3M | ||
| Q3 24 | $183.9M | $749.6M | ||
| Q2 24 | $184.7M | $879.3M | ||
| Q1 24 | $224.9M | $892.2M |
| Q4 25 | $428.0M | $1.3B | ||
| Q3 25 | $538.6M | $1.3B | ||
| Q2 25 | $439.0M | $1.5B | ||
| Q1 25 | $462.5M | $1.6B | ||
| Q4 24 | $543.7M | $1.6B | ||
| Q3 24 | $661.6M | $1.5B | ||
| Q2 24 | $556.8M | $1.6B | ||
| Q1 24 | $575.8M | $1.6B |
| Q4 25 | 0.58× | 0.54× | ||
| Q3 25 | 0.55× | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 0.00× | 0.75× | ||
| Q3 24 | 0.51× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.41× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $15.6M | $43.7M |
| Free Cash FlowOCF − Capex | $15.0M | $43.5M |
| FCF MarginFCF / Revenue | 7.4% | 22.1% |
| Capex IntensityCapex / Revenue | 0.3% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-24.0M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.6M | $43.7M | ||
| Q3 25 | $12.2M | $60.8M | ||
| Q2 25 | $8.8M | $12.0M | ||
| Q1 25 | $-57.2M | $35.5M | ||
| Q4 24 | $-25.1M | $33.1M | ||
| Q3 24 | $-2.2M | $53.9M | ||
| Q2 24 | $605.0K | $53.2M | ||
| Q1 24 | $-98.4M | $49.1M |
| Q4 25 | $15.0M | $43.5M | ||
| Q3 25 | $11.2M | $57.0M | ||
| Q2 25 | $8.3M | $9.3M | ||
| Q1 25 | $-58.5M | $26.9M | ||
| Q4 24 | $-25.5M | $31.0M | ||
| Q3 24 | $-4.2M | $49.8M | ||
| Q2 24 | $-111.0K | $51.6M | ||
| Q1 24 | $-99.4M | $46.3M |
| Q4 25 | 7.4% | 22.1% | ||
| Q3 25 | 6.9% | 31.7% | ||
| Q2 25 | 5.4% | 5.1% | ||
| Q1 25 | -43.5% | 15.9% | ||
| Q4 24 | -12.7% | 16.6% | ||
| Q3 24 | -1.6% | 29.6% | ||
| Q2 24 | -0.1% | 29.0% | ||
| Q1 24 | -63.9% | 27.7% |
| Q4 25 | 0.3% | 0.1% | ||
| Q3 25 | 0.6% | 2.2% | ||
| Q2 25 | 0.3% | 1.5% | ||
| Q1 25 | 1.0% | 5.1% | ||
| Q4 24 | 0.2% | 1.1% | ||
| Q3 24 | 0.8% | 2.4% | ||
| Q2 24 | 0.4% | 0.9% | ||
| Q1 24 | 0.6% | 1.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× | ||
| Q1 24 | — | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GPRO
| Subscription And Services | $106.3M | 53% |
| Other | $95.4M | 47% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
